Robert Königsberg

1.9k total citations
31 papers, 1.5k citations indexed

About

Robert Königsberg is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Robert Königsberg has authored 31 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 8 papers in Cancer Research and 7 papers in Molecular Biology. Recurrent topics in Robert Königsberg's work include Cancer Risks and Factors (7 papers), Estrogen and related hormone effects (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Robert Königsberg is often cited by papers focused on Cancer Risks and Factors (7 papers), Estrogen and related hormone effects (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Robert Königsberg collaborates with scholars based in Austria, Germany and United States. Robert Königsberg's co-authors include Georg Pfeiler, Christian Dittrich, Matthias Pinter, Markus Peck‐Radosavljevic, A Maieron, Wolfgang Sieghart, H. Huber, Johannes Drach, H. Kaufmann and Marcus Hudec and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Radiology.

In The Last Decade

Robert Königsberg

31 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Königsberg Austria 16 676 536 365 357 354 31 1.5k
Pilar Lardelli Spain 19 643 1.0× 298 0.6× 160 0.4× 141 0.4× 276 0.8× 71 1.5k
Hiroki Yoshida Japan 15 272 0.4× 304 0.6× 394 1.1× 206 0.6× 65 0.2× 55 1.3k
José María Sayagués Spain 23 292 0.4× 367 0.7× 294 0.8× 216 0.6× 26 0.1× 66 1.3k
D.W. Miles United Kingdom 24 1.0k 1.5× 616 1.1× 95 0.3× 579 1.6× 38 0.1× 55 1.8k
Brian Dolinski United States 15 321 0.5× 463 0.9× 124 0.3× 97 0.3× 86 0.2× 18 1.1k
Laura Galluzzo Argentina 13 425 0.6× 876 1.6× 29 0.1× 600 1.7× 383 1.1× 40 1.6k
Wolfgang Eisterer Austria 21 712 1.1× 564 1.1× 425 1.2× 109 0.3× 29 0.1× 95 1.7k
Yu Kato Japan 15 1.8k 2.6× 472 0.9× 36 0.1× 215 0.6× 262 0.7× 30 2.7k
Cristina Rabascio Italy 17 556 0.8× 476 0.9× 272 0.7× 243 0.7× 24 0.1× 33 1.1k
M. Y. Gordon United Kingdom 22 290 0.4× 453 0.8× 714 2.0× 65 0.2× 102 0.3× 65 1.4k

Countries citing papers authored by Robert Königsberg

Since Specialization
Citations

This map shows the geographic impact of Robert Königsberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Königsberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Königsberg more than expected).

Fields of papers citing papers by Robert Königsberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Königsberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Königsberg. The network helps show where Robert Königsberg may publish in the future.

Co-authorship network of co-authors of Robert Königsberg

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Königsberg. A scholar is included among the top collaborators of Robert Königsberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Königsberg. Robert Königsberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dittrich, Christian, et al.. (2018). Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. Investigational New Drugs. 37(1). 127–138. 1 indexed citations
2.
3.
Königsberg, Robert, et al.. (2013). Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab. Radiology and Oncology. 48(2). 184–188. 6 indexed citations
4.
Königsberg, Robert, et al.. (2013). Luminal A and Luminal B subtypes in patients with breast cancer 65 years of age and older.. Journal of Clinical Oncology. 31(15_suppl). 549–549. 1 indexed citations
5.
Pinter, Matthias, Florian Hucke, Ivo Graziadei, et al.. (2012). Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. Radiology. 263(2). 590–599. 174 indexed citations
6.
Königsberg, Robert, Georg Pfeiler, Andreas Brunner, et al.. (2012). Tumor characteristics and recurrence patterns in triple negative breast cancer: A comparison between younger (<65) and elderly (⩾65) patients. European Journal of Cancer. 48(16). 2962–2968. 23 indexed citations
7.
Königsberg, Robert, Georg Pfeiler, Marcus Hudec, et al.. (2011). Prognostic Assessment and Adjuvant Treatment Strategies Within Early-Stage, Sporadic Triple Negative Breast Cancer Patients. Cancer Investigation. 29(2). 180–186. 5 indexed citations
8.
Königsberg, Robert, Eva Obermayr, Giovanna Bises, et al.. (2011). Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncologica. 50(5). 700–710. 206 indexed citations
9.
10.
Pfeiler, Georg, Robert Königsberg, Thomas Geisendorfer, et al.. (2011). Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric. 14(3). 339–344. 42 indexed citations
11.
Pinter, Matthias, Wolfgang Sieghart, Florian Hucke, et al.. (2011). Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Alimentary Pharmacology & Therapeutics. 34(8). 949–959. 63 indexed citations
12.
Wlcek, Katrin, Cem Ekmekçioğlu, Susanne Humpeler, et al.. (2011). Melatonin receptors, melatonin metabolizing enzymes and cyclin D1 in human breast cancer. Journal of Receptors and Signal Transduction. 31(2). 180–187. 12 indexed citations
13.
Pinter, Matthias, Wolfgang Sieghart, Florian Hucke, et al.. (2011). Prognostic factors in patients with hepatocellular carcinoma treated with Sorafenib. Zeitschrift für Gastroenterologie. 49(5). 1 indexed citations
14.
Pfeiler, Georg, Robert Königsberg, Brigitte Mlineritsch, et al.. (2011). Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial.. Journal of Clinical Oncology. 29(15_suppl). 514–514. 4 indexed citations
15.
Königsberg, Robert, Margit Gneist, Georg Pfeiler, et al.. (2010). Circulating tumor cells in metastatic colorectal cancer: Efficacy and feasibility of different enrichment methods. Cancer Letters. 293(1). 117–123. 49 indexed citations
16.
Pfeiler, Georg, Gernot Hudelist, P Wülfing, et al.. (2010). Impact of AdipoR1 expression on breast cancer development. Gynecologic Oncology. 117(1). 134–138. 25 indexed citations
17.
Ekmekçioğlu, Cem, Walter Jäger, M. Klimpfinger, et al.. (2009). Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. Journal of Pineal Research. 46(4). 422–432. 29 indexed citations
18.
Königsberg, Robert, Walter Jäger, Theresia Thalhammer, et al.. (2008). Cell Cycle Dysregulation Influences Survival in High Risk Breast Cancer Patients. Cancer Investigation. 26(7). 734–740. 17 indexed citations
19.
Königsberg, Robert, J Ackermann, H. Kaufmann, et al.. (2000). Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia. 14(11). 1975–1979. 55 indexed citations
20.
Filipits, Martin, Johannes Drach, Gudrun Pohl, et al.. (1999). Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma.. PubMed. 5(9). 2426–30. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pilar Lardelli Breakdown of academic impact, for papers by Hiroki Yoshida Breakdown of academic impact, for papers by José María Sayagués Breakdown of academic impact, for papers by D.W. Miles Breakdown of academic impact, for papers by Brian Dolinski Breakdown of academic impact, for papers by Laura Galluzzo Breakdown of academic impact, for papers by Wolfgang Eisterer Breakdown of academic impact, for papers by Yu Kato Breakdown of academic impact, for papers by Cristina Rabascio Breakdown of academic impact, for papers by M. Y. Gordon
Rankless by CCL
2026